These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12030634)

  • 1. Overactive bladder patients and role of the pharmacist.
    Stewart K; McGhan WF; Offerdahl T; Corey R
    J Am Pharm Assoc (Wash); 2002; 42(3):469-76; quiz 477-8. PubMed ID: 12030634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder.
    McGhan WF
    Am J Manag Care; 2001 Mar; 7(2 Suppl):S62-75. PubMed ID: 11261409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining overactive bladder: epidemiology and burden of disease.
    Tubaro A
    Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated economic costs of overactive bladder in the United States.
    Hu TW; Wagner TH; Bentkover JD; LeBlanc K; Piancentini A; Stewart WF; Corey R; Zhou SZ; Hunt TL
    Urology; 2003 Jun; 61(6):1123-8. PubMed ID: 12809878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
    Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K
    Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economic impact of overactive bladder symptoms in Japan].
    Inoue S; Kobayashi M; Sugaya K
    Nihon Hinyokika Gakkai Zasshi; 2008 Nov; 99(7):713-22. PubMed ID: 19068687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin extended-release: a review of its use in the management of overactive bladder.
    Siddiqui MA; Perry CM; Scott LJ
    Drugs; 2004; 64(8):885-912. PubMed ID: 15059046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China.
    Xu D; Gao J; Wang X; Huang L; Wang K
    J Diabetes Complications; 2017 Aug; 31(8):1254-1258. PubMed ID: 28533105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
    Brunton S; Kuritzky L
    Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
    Qin L; Luo X; Zou KH; Snedecor SJ
    J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.
    Scheife R; Takeda M
    Clin Ther; 2005 Feb; 27(2):144-53. PubMed ID: 15811477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related consequences of overactive bladder.
    Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.